EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation

Lijing Xia, Xiong Lei, Liwen Zhou, Xiling Liu, Pengcheng Lin, Tongtong Hou, Hanyan Xu, Shanshan Su, Li Yang, Chengshui Chen, Yuping Li

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Lijing Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Interventional Pulmonology of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The First Affiliated Hos…. Hauptthemen laut MEDLINE: Acute Lung Injury, Hydrazines, Anti-Inflammatory Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wenzhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/PURPOSE: Acute lung injury (ALI) is a pulmonary condition resulting from dysregulated inflammation and disruption of the alveolar-capillary barrier. Natsudaidain has the potential to alleviate inflammatory diseases; however, its role in alleviates ALI remains unknown. This research aims to investigate the impact of natsudaidain in the treatment of ALI. STUDY DESIGN/METHODS: Network pharmacology was employed to examine the potential targets and mechanisms of natsudaidain in treatment of ALI. In vivo experiments utilized LPS-treated mice, with lung injury evaluated through histopathological examination and the level of apoptosis assed using TUNEL staining. In vitro experiments were conducted using MLE-12 cells stimulated with t-BHP to measure reactive oxygen species levels and assess apoptosis. The expression levels of relevant pathway proteins were confirmed using western blot analysis. RESULTS: Network pharmacology analyses indicate that natsudaidain has the potential to upregulate the PI3K/Akt signaling pathway and reducing apoptosis. In vivo experiments demonstrated that natsudaidain alleviated LPS-induced ALI and decreased apoptosis levels. In vitro experiments confirmed that natsudaidain reduced the apoptosis rate in t-BHP-stimulated MLE-12 cells. Western blot reveled natsudaidain increased levels of p-PI3K and p-AKT and a reduction in P53 levels, in both LPS-induced mice and t-BHP-stimulated MLE-12 cells. Furhermore, the P53 activator C16-ceramide negated the protective effects of natsudaidain on the apoptosis of MLE-12 cells. CONCLUSION: Natsudaidain is a effective therapeutic agent for ALI. Its protective effect against ALI is primarily achieved by reducing apoptosis in MLE-12 cells through the upregulation of the PI3K/Akt signaling pathway and the downregulation of the P53 signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryHydrazinesAnti-Inflammatory AgentsAnimalsApoptosisTumor Suppressor Protein p53Signal TransductionProto-Oncogene Proteins c-aktMicePhosphatidylinositol 3-KinasesLipopolysaccharidesCell LineNetwork PharmacologyMaleLungDisease Models, Animal

Stichwörter der Autor:innen

Acute lung injuryApoptosisNatsudaidainP-AKTP-PI3KP53

Substanzen

Tumor Suppressor Protein p53Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesLipopolysaccharidesHydrazinesTrp53 protein, mouseAnti-Inflammatory Agents

Autor:innen und Institutionen

  • The Key Laboratory of Interventional Pulmonology of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Emergency, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • The Key Laboratory of Interventional Pulmonology of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Electronic addres…

Förderung

  • Wenzhou Municipal Science and Technology Bureau

Zitieren

APA

Xia, L., Lei, X., Zhou, L., Liu, X., Lin, P., Hou, T., Xu, H., Su, S., Yang, L., Chen, C., & Li, Y. (2025). Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115396

Vancouver

Xia L, Lei X, Zhou L, Liu X, Lin P, Hou T, et al. Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115396

BibTeX
@article{Xia2025,
  author = {Xia, Lijing and Lei, Xiong and Zhou, Liwen and Liu, Xiling and Lin, Pengcheng and Hou, Tongtong and Xu, Hanyan and Su, Shanshan and Yang, Li and Chen, Chengshui and Li, Yuping},
  title = {Natsudaidain alleviates acute lung injury through the PI3K/Akt and P53 signaling pathways by inhibiting MLE-12 apoptosis: a network pharmacology study and experimental validation},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115396}
}
Kostenlos starten →